Physicians' Academy for Cardiovascular Education
The CANVAS biomarker substudy showed that canagliflozin delays the expected increase in CV biomarkers in T2DM patients. It also reduces the risk of HF and renal disease events irrespective of biomarker levels at baseline.
Prof. Sattar shares his thoughts on why high triglycerides reflect ectopic fat and how this relationship may help to motivate patients to sustain weight improvements and lower CV and diabetes risks.
Three speakers present the KDIGO guidelines, evidence of studies with GLP-1RAs and kidney outcomes and tell us what we can expect in the near future with regard to GLP-1RAs in nephrology.
How should you treat a patient with T2DM and multiple CV risk factors? In this series, two duos both present such a case and discuss the optimal treatment strategy.
Watch a discussion by three experts on the role of GLP-1RA in preventing CKD in patients with diabetes.
"Multifactorial risk factor approach is important for patients with T2DM", says Adie Viljoen. He presents a case of a patient with T2DM and multiple CV risk factors. Together with prof. Marx, he discusses the treatment plan for this patient.
Prof. Marx and Prof. Lehrke discuss a case of a 64-year old patient with T2DM and acute MI. What are the treatment options in this patient?
The American Diabetes Association (ADA) has made important updates to the Standard of Medical Care in Diabetes 2022. Updates include new data on finerenone in T2DM and CKD, SGLT2i in T2DM and calculating eGFR.
In this video, Prof. Tuttle discusses GLP-1RAs for CVD risk reduction and preservation of kidney function in CKD. Moreover, she talks about multidisciplinary team care for patients with T2DM and CKD.
By pooling data from 20 RCTs, researchers analyzed the adverse event rate with empagliflozin versus placebo in 2367 T2DM patients with moderate to severe CKD.
In this video, three physicians talk about the results of the FIDELIO-DKD and FIGARO-DKD studies and the FIDELLITY analysis and discuss the clinical implications of initiating nonsteroidal MRAs in patients with CKD and T2DM.
Although American cardiologists are increasingly prescribing SGLT2is and GLP‐1RAs since 2015, they accounted for <2% of all use in 2020. This could contribute to the known undertreatment of T2DM patients with high CVD risk.
